Show simple item record

dc.contributor.authorTran, Anna T
dc.contributor.authorMandall, P
dc.contributor.authorSwindell, Ric
dc.contributor.authorHoskin, P
dc.contributor.authorBottomley, D
dc.contributor.authorLogue, John P
dc.contributor.authorWylie, James P
dc.date.accessioned2013-08-06T14:35:48Z
dc.date.available2013-08-06T14:35:48Z
dc.date.issued2013-07-09
dc.identifier.citationBiochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother Oncolen_GB
dc.identifier.issn1879-0887
dc.identifier.pmid23849172
dc.identifier.doi10.1016/j.radonc.2013.05.030
dc.identifier.urihttp://hdl.handle.net/10541/297452
dc.description.abstractRoutine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncologyen_GB
dc.titleBiochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UK. Electronic address: anna.tran@christie.nhs.uk.en_GB
dc.identifier.journalRadiotherapy and Oncologyen_GB
html.description.abstractRoutine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.


Files in this item

This item appears in the following Collection(s)

Show simple item record